I can't remember where I read it, but I believe AMBS stated they would report univariate for some time. My assumption is they will report univariate until the CLIA package is submitted. ICON is reproducing the results in their lab and likely optimizing the eventual multivariate results for the commercial test. It likely does not make sense to report multivariate before that time until they have had an opportunity to do this work as it would be premature. Quite frankly, it doesn't matter in the long run. The univariate results from the bridge test LP002 is enough to expand the ICON partnership in the near term.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links